The Dales Report lists Small Pharma as one of 10 Psychedelic Companies To Watch In 2022

Small Pharma (CVE: DMT) (OTCMKTS: DMTTF) are delighted to be highlighted as one of the 10 Psychedelic Companies to watch in 2022 according to the The Dales Report.

The write includes highlights of Small Pharma feats of success in 2021 such as starting to trade on the TSX Venture Exchange in May, 2021.  Other highlights of 2021 include the completion of the first phase of clinical trials of DMT in combination with supportive psychotherapy and commencement of a phase 2a trial. October was a particularly busy month for Small Pharma: as it was upgraded to the OTCQB and granted a fast-track designation by the UK heath regulator for DMT-assisted therapy for major depression. As part of the company’s growing intellectual property portfolio, Small Pharma was also granted a European patent for ketamine-based treatment of depressive disorders.  

In 2022, Small Pharma is set to have another big year with results from our Phase IIA DMT-assisted therapy trial due in the first half of the year.


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: